Cas:203663-26-7 N-Boc-4-(hydroxymethyl)-1,2,3,6-tetrahydropyridine manufacturer & supplier

Chemical Name:N-Boc-4-(hydroxymethyl)-1,2,3,6-tetrahydropyridine

CAS.NO:203663-26-7

Synonyms:N-Boc-4-(hydroxymethyl)-1,2,3,6-tetrahydropyridine;TERT-BUTYL 4-(HYDROXYMETHYL)-5,6-DIHYDROPYRIDINE-1(2H)-CARBOXYLATE

Molecular Formula:C₁₁H₁₉NO₃

Molecular Weight:213.27300

HS Code:2933399090

Physical and Chemical Properties:

Melting point:N/A

Boiling point:N/A

Density:N/A

Index of Refraction:

PSA:49.77000

Exact Mass:213.13600

LogP:1.48380

Material Safety Information (Applicable for Hazard Chemicals)

RIDADR:

Packing Group:

Contact us for information like N-Boc-4-(hydroxymethyl)-1,2,3,6-tetrahydropyridine chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,TERT-BUTYL 4-(HYDROXYMETHYL)-5,6-DIHYDROPYRIDINE-1(2H)-CARBOXYLATE physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,TERT-BUTYL 4-(HYDROXYMETHYL)-5,6-DIHYDROPYRIDINE-1(2H)-CARBOXYLATE Use and application,TERT-BUTYL 4-(HYDROXYMETHYL)-5,6-DIHYDROPYRIDINE-1(2H)-CARBOXYLATE technical grade,usp/ep/jp grade.

Related News: From the three-month point onward, 84.5% of uMRD patients maintained that deep remission in the blood to the 12-month assessment. These data show the new combo can deliver “very durable remissions” for the vast majority of patients, Tendler said. N-Boc-4-(hydroxymethyl)-1,2,3,6-tetrahydropyridine manufacturer Retrogenix and Resonant Therapeutics, Inc. recently announced they have entered into a non-exclusive strategic partnership to identify the targets of Resonant antibodies directed against the tumor microenvironment. N-Boc-4-(hydroxymethyl)-1,2,3,6-tetrahydropyridine supplier Under the strict supervision of environmental protection, it has helped the API industry to continuously optimize its product structure, realize industrial upgrading, and transition to the development of high-end APIs. N-Boc-4-(hydroxymethyl)-1,2,3,6-tetrahydropyridine vendor From the three-month point onward, 84.5% of uMRD patients maintained that deep remission in the blood to the 12-month assessment. These data show the new combo can deliver “very durable remissions” for the vast majority of patients, Tendler said. N-Boc-4-(hydroxymethyl)-1,2,3,6-tetrahydropyridine factory From the three-month point onward, 84.5% of uMRD patients maintained that deep remission in the blood to the 12-month assessment. These data show the new combo can deliver “very durable remissions” for the vast majority of patients, Tendler said.